Key result
Upcoming RCT tests early TEVAR against SMT for 5-year mortality in uncomplicated type B aortic dissection.
Why the study?
While TEVAR improves aortic morphology in uncomplicated type B aortic dissection, evidence for improved overall survival, cost data, and quality-of-life impact is lacking.
Does early TEVAR added to standard medical therapy improve survival at 5 years in patients with uncomplicated type B aortic dissection?
RCT (n=554)
Open-label
1:1 allocation via REDCap, stratified by clinical sites
Yes
Does early TEVAR added to standard medical therapy improve survival at 5 years in patients with uncomplicated type B aortic dissection?
Answers are grounded in this paper and cite their sources.
This study protocol outlines a randomized trial to determine if early TEVAR added to standard medical therapy improves 5-year survival in patients with uncomplicated type B aortic dissection.
Background: Contemporary management of uncomplicated type B aortic dissections (uTBAD) is based on the acuity and various morphological features. Medical therapy is mandatory, while the risks of early thoracic endovascular aortic repair (TEVAR) are balanced against the potential for rupture, complex surgery, and death. Improved aortic morphology following TEVAR is documented, but evidence for improved overall survival is lacking. The costs and impact on quality-of-life are also needed. Methods: The trial is a randomized, open label, superiority clinical trial with parallel assignment of subjects at 23 clinical sites in Denmark, Norway, Sweden, Finland, and Iceland. Eligibility includes patients aged ≥ 18 with uTBAD of < 4 weeks duration. Recruited subjects will be randomized to either standard medical therapy (SMT) or SMT+TEVAR, where TEVAR must be performed between 2-12 weeks from the onset of symtpoms. Discussion: This trial will evaluate the primary question of whether early TEVAR improves survival at 5 years among uTBAD patients. Moreover, the costs and the impact on quality-of-life should provide sorely needed data on other factors that play a role in treatment strategy decisions. The common Nordic healthcare model, with inclusion of all aortic centers, provides a favorable setting for carrying out this trial, while the robust healthcare registries ensure data validity. Trial registration: clinicaltrials.gov: NCT05215587, posted January 31, 2022
No takes yet. Share an insight, caveat, or question.
Rudolf et al. (2023) conducted an RCT in Uncomplicated type B aortic dissection (uTBAD) (n=554). TEVAR + Standard Medical Therapy vs. Standard Medical Therapy was evaluated on All-cause mortality at 5 years. Early TEVAR combined with standard medical therapy will be evaluated against standard medical therapy alone for its effect on 5-year all-cause mortality in a planned randomized controlled trial of 554 patients with uncomplicated type B aortic dissection.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: